Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Federal Trade Commission
Fish and Richardson
AstraZeneca
Moodys
Teva
Boehringer Ingelheim
Cantor Fitzgerald
Queensland Health

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,418,250

« Back to Dashboard

Title: Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
Abstract:Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.
Inventor(s): Finkelstein; Joseph A. (Philadelphia, PA), Keenan; Richard M. (Malvern, PA), Weinstock; Joseph (Phoenixville, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Filing Date:Jun 14, 1993
Application Number:08/076,609
Claims:1. A compound which is (E)-3-[2-n-butyl-1-{(4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a pharmaceutical carrier and (E)-3-[2-n-butyl-1-{(4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid.

3. A method of antagonizing angiotensin II receptors which comprises administering to a subject in need thereof an effective amount (E)-3-[2-n-butyl-1-{(4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid.

4. A method of treating hypertension which comprises administering to a subject in need thereof an effective amount of (E)-3-[2-n-butyl-1-{(4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid.

5. A method of treating congestive heart failure which comprises administering to a subject in need thereof an effective amount of (E)-3-[2-n-butyl-1-{(4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid.

6. A method of treating renal failure which comprises administering to a subject in need thereof an effective amount of (E)-3-[2-n-butyl-1-{(4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid.

7. A method of treating glaucoma which comprises administering to a subject in need thereof an effective amount of (E)-3-[2-n-butyl-1-{(4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Fish and Richardson
Dow
Julphar
Colorcon
Citi
Accenture
Cantor Fitzgerald
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.